These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 26864100)

  • 1. Antibodies as leading tools to unlock the therapeutic potential in human disease.
    Martin F
    Immunol Rev; 2016 Mar; 270(1):5-7. PubMed ID: 26864100
    [No Abstract]   [Full Text] [Related]  

  • 2. Tailor-made antibody therapeutics.
    Chowdhury PS; Wu H
    Methods; 2005 May; 36(1):11-24. PubMed ID: 15848071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources.
    Lipman NS; Jackson LR; Trudel LJ; Weis-Garcia F
    ILAR J; 2005; 46(3):258-68. PubMed ID: 15953833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant polyclonal antibodies: the next generation of antibody therapeutics?
    Haurum JS
    Drug Discov Today; 2006 Jul; 11(13-14):655-60. PubMed ID: 16793535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can super-antibody drugs be tamed?
    Nature; 2006 Apr; 440(7086):855-6. PubMed ID: 16612349
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutic antibodies in multiple sclerosis.
    Goebels N; Becher B
    Neurodegener Dis; 2008; 5(1):5-7. PubMed ID: 18075268
    [No Abstract]   [Full Text] [Related]  

  • 7. The nature of an ideal therapeutic human antibody.
    Glassy MC; Koda K
    Expert Opin Biol Ther; 2002 Jan; 2(1):1-2. PubMed ID: 11772335
    [No Abstract]   [Full Text] [Related]  

  • 8. Preparation and use of therapeutic antibodies primarily of human origin.
    Stiehm ER; Keller MA; Vyas GN
    Biologicals; 2008 Nov; 36(6):363-74. PubMed ID: 18789721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible applications of antibodies or their genes in cancer therapy.
    Kuroki M; Huang J; Shibaguchi H; Tanaka T; Zhao J; Luo N; Hachimine K; Kinugasa T; Maekawa S; Enatsu S; Hamanaka W; Fukami T; Kuroki M
    Anticancer Res; 2006; 26(6A):4019-25. PubMed ID: 17195452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered antibody approaches for Alzheimer's disease immunotherapy.
    Robert R; Wark KL
    Arch Biochem Biophys; 2012 Oct; 526(2):132-8. PubMed ID: 22475448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies as a source of anti-infective peptides: an update.
    Magliani W; Giovati L; Ciociola T; Sperindè M; Santinoli C; Conti G; Conti S; Polonelli L
    Future Microbiol; 2015; 10(7):1163-75. PubMed ID: 26119210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antibodies as medication].
    Kurki P; Jalanko H
    Duodecim; 1995; 111(8):788-96. PubMed ID: 8681839
    [No Abstract]   [Full Text] [Related]  

  • 13. The expanding role of therapeutic antibodies.
    Salemi S; Markovic M; Martini G; D'Amelio R
    Int Rev Immunol; 2015 May; 34(3):202-64. PubMed ID: 24471447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic antibodies--delivering the promise?
    Hale G
    Adv Drug Deliv Rev; 2006 Aug; 58(5-6):633-9. PubMed ID: 16822575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Monoclonal antibodies and chemotherapy: therapeutic indications].
    Carrozza F
    Suppl Tumori; 2004; 3(4):S127-9. PubMed ID: 15206238
    [No Abstract]   [Full Text] [Related]  

  • 16. Breakthrough of the year 2013. Cancer immunotherapy.
    Couzin-Frankel J
    Science; 2013 Dec; 342(6165):1432-3. PubMed ID: 24357284
    [No Abstract]   [Full Text] [Related]  

  • 17. Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb.
    Morse MA
    Curr Opin Mol Ther; 2005 Dec; 7(6):588-97. PubMed ID: 16370382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-chain antibodies as diagnostic tools and therapeutic agents.
    Hagemeyer CE; von Zur Muhlen C; von Elverfeldt D; Peter K
    Thromb Haemost; 2009 Jun; 101(6):1012-9. PubMed ID: 19492141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody engineering: an overview.
    O'Kennedy R; Roben P
    Essays Biochem; 1991; 26():59-75. PubMed ID: 1778186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies to extend plasma half-lives of recombinant antibodies.
    Kontermann RE
    BioDrugs; 2009; 23(2):93-109. PubMed ID: 19489651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.